PYXS · Pyxis Oncology, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements were issued.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | $13.86M | $16.15M | — | — | — | — | |
| — | $2.39M | $475K | — | — | — | — | |
| — | $11.47M | $15.67M | — | — | — | — | |
| — | 82.77% | 97.06% | — | — | — | — | |
| $75.56M | $73.7M | $58.75M | $49.59M | $86.13M | $51.05M | $9.05M | |
| $25.2M | $22.19M | $25.42M | $32.61M | $37.35M | $18.66M | $3.85M | |
| — | $4.51M | $2.98M | $1.93M | $709K | $647K | $469K | |
| — | — | — | $82.2M | $123.48M | $69.72M | $12.89M | |
| -$92.11M | -$84.42M | -$89.46M | -$82.2M | -$123.48M | -$69.72M | -$12.89M | |
| — | -609.18% | -554.07% | — | — | — | — | |
| — | -$79.91M | -$86.48M | -$80.27M | -$122.77M | -$69.07M | -$12.43M | |
| $746K | $650K | $930K | $1.84M | $2.76M | $23K | $66K | |
| $4.48M | $6.19M | $9.97M | $8.41M | $2.76M | -$6.03M | $66K | |
| — | — | — | — | $0 | -$231K | — | |
| — | -$78.24M | -$79.5M | -$73.79M | — | — | — | |
| — | $1.39M | -$2.16M | — | — | — | — | |
| -$88.73M | -$79.62M | -$77.33M | -$73.79M | -$120.72M | -$75.98M | -$12.83M | |
| — | -574.55% | -478.95% | — | — | — | — | |
| -$88.73M | -$79.74M | -$77.22M | -$73.73M | -$120.72M | — | — | |
| USD/shares | — | -$1.28 | -$1.32 | -$1.85 | -$3.65 | -$8.95 | — |
| USD/shares | — | -$1.28 | -$1.32 | -$1.85 | -$3.65 | -$8.95 | — |
| shares | — | 62.14M | 58.45M | 39.9M | 33.03M | 8.49M | 1.03M |
| shares | — | 62.14M | 58.45M | 39.9M | 33.03M | 8.49M | 1.03M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 314 similar-size Biotechnology companies (of 546 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Sale of Royalty Rights | $11,038,000 | $8,000,000 |
| Milestone Revenue | $2,820,000 | $0 |
| Royalty | $0 | $8,146,000 |
| Royalty Revenues and Sale of Royalty Rights | — | $16,146,000 |